EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro

Johanna M Jansen iD, Wilian Cortopassi, Daniel Fuller, Peter Ertl iD, Eric Fang, Rishi Raj Gupta iD, Weiping Jia, Jan Jiricek, Mark Knapp, Andreas Lingel iD, John Manchester, Stephanie Moquin iD und 16 weitere

Journal of Chemical Information and Modeling · 28.09.2026 · 66 (18) · 11847-11861

DOI: 10.1021/acs.jcim.6c01654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Chemical Information and Modeling, online erschienen am 16.09.2026. Verfasst von Johanna M Jansen und 27 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Biomedical Research , Emeryville, California94608, United States. Hauptthemen laut MEDLINE: Drug Discovery, 14-3-3 Proteins, SARS-CoV-2, Estrogen Receptor alpha. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Scope is a hit-finding concept that explores a chemical space in between fragments and fully elaborated molecules from traditional low molecular weight (LMW) libraries. It emphasizes high medicinal chemistry tractability through a focus on compound quality, ligand efficiency, and selected physical-chemical property ranges. The Scope chemical space definition seeks to strike a balance between the ability to cover chemical space with a 10k–50k compound set for medium-throughput screening and obtaining hits with sufficient functionality to yield low- to mid-micromolar potency. Scope chemical space is distinct from other rule-based chemical spaces, and we introduce the concept of Scope ring systems (ring-X-ring) as both a foundation for intentional functionalization targeting sufficient potency and as an organizing principle for characterizing and enhancing compound libraries. A Scope screening set has been designed from the Scope chemical space for hit finding with SPR, native mass spectrometry, DSF, and biochemical methods. This Scope set maintains comparable primary hit rates to general diversity sets even when screening at higher concentrations, which allows for efficient hit validation. The Scope set outperforms diversity sets when considering ligand efficiency and hit rates after counter-screening, which makes it a preferred set. Case studies include the trypanosomal CLK1 kinase target, a molecular glue project with 14–3–3 and estrogen receptor-α, and the SARS-CoV-2 main protease. These studies exemplify how the 10k Scope set delivers diverse and ligand-efficient hits with tractable potency across diverse binding sites and support the idea that a carefully designed 10k Scope set can provide meaningful diversity for screening in a broad drug discovery portfolio. The Scope principles have demonstrated value in hit-finding campaigns and have changed practices for compound acquisition, hit-list triaging, and screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Discovery14-3-3 ProteinsSARS-CoV-2Estrogen Receptor alphaProtein Serine-Threonine KinasesLigandsHumansSmall Molecule Libraries

Substanzen

Ligands14-3-3 ProteinsEstrogen Receptor alphaProtein Serine-Threonine KinasesSmall Molecule Libraries

Autor:innen und Institutionen

  • Novartis Biomedical Research , Emeryville, California94608, United States.
  • Novartis Biomedical Research, Cambridge, Massachusetts02139, United States.
  • Novartis Biomedical Research, BaselCH-4056, Switzerland.

ORCID-Profile: Johanna M Jansen, Peter Ertl, Rishi Raj Gupta, Andreas Lingel, Stephanie Moquin, Olivier Rene, Ansgar Schuffenhauer, Colin Skepper, Sarah Williams

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Jansen, J. M., Cortopassi, W., Fuller, D., Ertl, P., Fang, E., Gupta, R. R., Jia, W., Jiricek, J., Knapp, M., Lingel, A., Manchester, J., Moquin, S., Moreau, R., Patra, D., Pedro, L., Pfister, K., Rene, O., Rudewicz, P., Saldivia, M., …, & Wartchow, C. (2026). The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro. Journal of Chemical Information and Modeling, 66(18), 11847-11861. https://doi.org/10.1021/acs.jcim.6c01654

Vancouver

Jansen JM, Cortopassi W, Fuller D, Ertl P, Fang E, Gupta RR, et al. The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro. Journal of Chemical Information and Modeling. 2026;66(18):11847-11861. doi:10.1021/acs.jcim.6c01654

BibTeX
@article{Jansen2026,
  author = {Jansen, Johanna M and Cortopassi, Wilian and Fuller, Daniel and Ertl, Peter and Fang, Eric and Gupta, Rishi Raj and Jia, Weiping and Jiricek, Jan and Knapp, Mark and Lingel, Andreas and Manchester, John and Moquin, Stephanie and Moreau, Robert and Patra, Debjani and Pedro, Liliana and Pfister, Keith and Rene, Olivier and Rudewicz, Patrick and Saldivia, Manuel and Schuffenhauer, Ansgar and Skepper, Colin and Stojkovic, Vanja and Tang, Jenny and Tosco, Paolo and Tsang, Tiffany and Williams, Sarah and Yan, Kelly and Wartchow, Charles},
  title = {The Scope Concept: Defined Chemical Space for Identifying Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α, and SARS-CoV-2 Mpro},
  journal = {Journal of Chemical Information and Modeling},
  year = {2026},
  volume = {66},
  number = {18},
  pages = {11847--11861},
  doi = {10.1021/acs.jcim.6c01654}
}
Kostenlos starten →